Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Sini V, Cassano A, Corsi D, De Laurentiis M, Gamucci T, Mauri M, Naso G, Roselli M, Ruggeri EM, Tonini G, Vici P, Zampa G, Marchetti P.
Sini V, et al. Among authors: tonini g.
Tumori. 2016 Oct 13;102(5):472-480. doi: 10.5301/tj.5000555. Epub 2016 Aug 23.
Tumori. 2016.
PMID: 27647231
Free article.
Review.